INS and cancer: In two included articles in the studies of Rahmani et al. (2019), those of Laskov et al. (2014), and Sivalingam et al. (2016)), it was reported that metformin decreased circulating insulin, glucose, and Ki-67 levels in cancer patients who did not meet our inclusion criteria such as English language and RCTs restriction.